Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $21.49 Analyst target: $46.89 Upside: 118.19%
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
See the full interactive analysis & chart →Informational only — not investment advice.